Casein peptides are most commonly used for atopic dermatitis (eczema) and allergies to milk. They are also used for high blood pressure, high cholesterol, anxiety, and many other conditions, but there is no good evidence to support most of these uses.
How does it work ?
Uses & Effectiveness ?
Likely Effective for
- Eczema (atopic dermatitis). Feeding infants a specific formula containing casein peptides (Nutramigen or Progestimil) with or without breastmilk for 4-6 months reduces the chances of getting eczema. This effect appears to last until at least 6 years of age.
- Prone to allergies and allergic reactions (atopic disease). Some research shows that feeding infants a specific formula containing casein peptides (Nutramigen) instead of cow's milk reduces the risk for allergies in infants whose parents have allergic conditions. This benefit appears to last until at least 6 years of age.
Possibly Effective for
- Excessive crying in infants (colic). Some research shows that feeding a specific formula containing casein peptides (Alimentum or Nutramigen) to infants with colic for 7 days reduces how often and how much the infant cries. In infants taking cow's milk formula who have colic, switching to a casein peptide formula (Nutramigen) reduces crying and colic for the first few days.
- Diabetes. Some research in adults with type 2 diabetes shows that eating casein peptides improves insulin and glucose levels after a meal. But it's not clear if taking casein peptides for a long time can improve blood sugar control.
- Food allergies. Specific formulas containing casein peptides are safe and do not cause allergic reactions in children who have an allergic reaction to cow's milk. These formulas include Alimentum, Damira 2000, Frisolac Allergycare, and Nutramigen.
- High blood pressure. Taking certain casein peptides, sometimes called lactotripeptides, seems to lower blood pressure by a small amount in people with high blood pressure.
- High levels of a chemical called bilirubin in the blood of newborns (neonatal jaundice). Some research shows that feeding infants a formula containing casein peptides (Nutramigen) instead of a formula containing whey protein (Enfamil) or breastmilk reduces the chance of getting jaundice.
Possibly Ineffective for
- Asthma. Most research shows that feeding infants a formula containing casein peptides, with or without breastmilk, for 4 months does not reduce the chance of developing asthma. But early research shows that this formula might decrease the amount of wheezing in some infants.
- Infant development. Most research shows that feeding premature, low-birth weight, and healthy infants a formula containing casein peptides does not increase or decrease growth when compared to breast milk, whey protein-based formula, rice hydrolysate formula, cow's milk formula, or amino acid-based formula. But some early research in infants with cow's milk allergy shows that taking casein peptides increases growth from 6-12 months of age better than soy milk.
Insufficient Evidence for
- Athletic performance. Limited research suggests that taking casein peptides improve strength in people practicing resistance training.
- Diarrhea. Early research in children with diarrhea shows that eating a diet containing casein peptides is less effective than a yogurt-based diet for reducing diarrhea.
- Muscle soreness caused by exercise. Early research in cyclists shows that drinking a carbohydrate beverage containing casein peptides during and after cycling reduces muscle soreness.
- Insomnia. Early research in people with sleep problems suggests that taking casein peptides might improve sleep.
- Physical performance in elderly adults. Early research in older men shows that taking casein peptides in addition to exercise does not improve muscle strength.
- High cholesterol.
- Intestinal disorders.
- Cancer prevention.
- Reducing stress.
- Other conditions.
Special Precautions and Warnings
Infants and children: Casein peptides are LIKELY SAFE for children and infants when taken by mouth. Most infants receiving casein peptide-based formulas do not experience side effects.
Milk allergy: People with milk allergy are allergic to the proteins contained in milk. They may also be allergic to fragments of milk proteins, such as casein peptides. If you have a milk allergy, it's best to avoid taking casein peptides. However, there are some specific casein peptide formulas that can be safely given to infants with milk allergy. These formulas are: Alimentum, Damira 2000, Frisolac Allergycare, and Nutramigen.
Surgery: Casein peptides might affect blood pressure. There is some concern that casein peptides might interfere with blood pressure control during and after surgery. Stop taking casein peptides at least 2 weeks before a scheduled surgery.
Medications for high blood pressure (Antihypertensive drugs) interacts with CASEIN PEPTIDES
Some casein peptides might decrease blood pressure. Taking casein peptides along with medications for high blood pressure might cause your blood pressure to go too low.
Some medications for high blood pressure include captopril (Capoten), enalapril (Vasotec), losartan (Cozaar), valsartan (Diovan), diltiazem (Cardizem), Amlodipine (Norvasc), hydrochlorothiazide (HydroDiuril), furosemide (Lasix), and many others.
Be cautious with this combination
- For diabetes: Casein peptides 12-17.6 grams, with or without leucine 5 grams, have been taken with meals.
- For high blood pressure: Certain casein peptides, sometimes called lactotripeptides, have been used in doses of 10.5 mg daily for 4-21 weeks.
- For eczema (atopic dermatitis): Specific casein peptide formulas (Nutramigen or Progestimil, Mead Johnson) have been used for 4-6 months.
- For allergies: A specific casein peptide formula (Nutramigen, Mead Johnson) has been used for 4-6 months.
- For cow's milk allergy: A variety of casein peptide formulas have been used, including Alimentum (Abbot Laboratories), Damira 2000 (Nutrition & Sante S.L.), Frisolac Allergycare (Friesland Nutrition), and Nutramigen (Mead Johnson).
- For diabetes: A specific casein peptide-based formula (Nutramigen, Mead Johnson) has been used when breastmilk is not available, starting at birth and lasting up to 6-8 months of age.
- For excessive crying in infants (colic): Specific casein peptide formulas have been used for up to 7 days. These include Alimentum (Abbot Laboratories) and Nutramigen (Mead Johnson).
- For high levels of a chemical called bilirubin in the blood of newborns (jaundice): Casein peptide formulas, including Nutramigen (Mead Johnson), have been used for 1-3 weeks.
Demling, R. H. and DeSanti, L. Effect of a hypocaloric diet, increased protein intake and resistance training on lean mass gains and fat mass loss in overweight police officers. Ann Nutr Metab 2000;44(1):21-29. View abstract.
Rzehak, P., Sausenthaler, S., Koletzko, S., Reinhardt, D., von, Berg A., Kramer, U., Berdel, D., Bollrath, C., Grubl, A., Bauer, C. P., Wichmann, H. E., and Heinrich, J. Long-term effects of hydrolyzed protein infant formulas on growth--extended follow-up to 10 y of age: results from the German Infant Nutritional Intervention (GINI) study. Am J Clin.Nutr 2011;94(6 Suppl):1803S-1807S. View abstract.
Agostoni C, Fiocchi A, Riva E, et al. Growth of infants with IgE-mediated cow's milk allergy fed different formulas in the complementary feeding period. Pediatr Allergy Immunol 2007;18(7):599-606. View abstract.
Borschel MW, Baggs GE, Barrett-Reis B. Growth of healthy term infants fed ready-to-feed and powdered forms of an extensively hydrolyzed casein-based infant formula: a randomized, blinded, controlled trial. Clin Pediatr (Phila) 2014;53(6):585-92. View abstract.
Borschel MW, Ziegler EE, Wedig RT, Oliver JS. Growth of healthy term infants fed an extensively hydrolyzed casein-based or free amino acid-based infant formula: a randomized, double-blind, controlled trial. Clin Pediatr (Phila) 2013;52(10):910-7. View abstract.
Chandra RK, Puri S, Hamed A. Influence of maternal diet during lactation and use of formula feeds on development of atopic eczema in high risk infants. BMJ 1989;299(693):228-30. View abstract.
Chanson-Rolle A, Aubin F, Braesco V, Hamasaki T, Kitakaze M. Influence of the Lactotripeptides Isoleucine-Proline-Proline and Valine-Proline-Proline on Systolic Blood Pressure in Japanese Subjects: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One. 2015;10(11):e0142235. View abstract.
Cicero AFG, Aubin F, Azais-Braesco V, Borghi C. Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials. Am J Hypertens. 2013;26(3):442-9. View abstract.
Cicero AFG, Colletti A, Rosticci M, et al. Effect of Lactotripeptides (Isoleucine-Proline-Proline/Valine-Proline-Proline) on Blood Pressure and Arterial Stiffness Changes in Subjects with Suboptimal Blood Pressure Control and Metabolic Syndrome: A Double-Blind, Randomized, Crossover Clinical Trial. Metab Syndr Relat Disord. 2016;14(3):161-6. View abstract.
Claustre J, Toumi F, Trompette A, et al. Effects of peptides derived from dietary proteins on mucus secretion in rat jejunum. Am J Physiol Gastrointest Liver Physiol 2002;283:G521-8. View abstract.
de Mattos AP, Ribeiro TC, Mendes PS, et al. Comparison of yogurt, soybean, casein, and amino acid-based diets in children with persistent diarrhea. Nutr Res 2009;29(7):462-9. View abstract.
Fekete AA, Givens DA, Lovegrove JA. Casein-derived lactotripeptides reduce systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials. Nutrients. 2015;7(1):659-81. View abstract.
Field KL, Kimball BA, Mennella JA, et al. Avoidance of hydrolyzed casein by mice. Physiol Behav 2008;93(1-2):189-99. View abstract.
Forsyth BW. Colic and the effect of changing formulas: a double-blind, multiple-crossover study. J Pediatr 1989;115(4):521-6. View abstract.
Geerts BF, van Dongen MG, Flameling B, et al. Hydrolyzed casein decreases posprandial glucose concentrations in T2DM patients irrespective of leucine content. J Diet Suppl 2011;8(3):280-92. View abstract.
Gill HS, Doull F, Rutherfurd KJ, Cross ML. Immunoregulatory peptides in bovine milk. Br J Nutr 2000;84:S111-7. View abstract.
Gourley GR, Arenda RA. beta-Glucuronidase and hyperbilirubinaemia in breast-fed and formula-fed babies. Lancet 1986;1:644-6. View abstract.
Gourley GR, Kreamer B, Arend R. The effect of diet on feces and jaundice during the first 3 weeks of life. Gastroenterology 1992;103(2):660-7. View abstract.
Gourley GR, Kreamer B, Cohnen M, Kosorok MR. Neonatal jaundice and diet. Arch Pediatr Adolesc Med 1999;153(2):184-8. View abstract.
Gourley GR, Kreamer BL, Cohnen M. Inhibition of beta-glucuronidase by casein hydrolysate formula. J Pediatr Gastroenterol 1997;25:267-72. View abstract.
Gourley GR, Li Z, Kreamer BL, Kosorok MR. A controlled, randomized, double-blind trial of prophylaxis against jaundice among breastfed newborns. Pediatrics 2005;116(2):385-91. View abstract.
Halken S, Hansen KS, Jacobsen HP, et al. Comparison of a partially hydrolyzed infant formula with two extensively hydrolyzed formulas for allergy prevention: a prospective, randomized study. Pediatr Allergy Immunol 2000;11(3):149-61. View abstract.
Harrison GG, Graver EJ, Vargas M, et al. Growth and adiposity of term infants fed whey-predominant or casein-predominant formulas or human milk. J Pediatr Gastroenterol Nutr 1987;6(5):739-47. View abstract.
Hautaniemi EJ, Tikkakoski AJ, Tahvanainen A, et al. Effect of fermented milk product containing lactotripeptides and plant sterol esters on haemodynamics in subjects with the metabolic syndrome--a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114(3):376-86. View abstract.
Horner K, Drummond E, O'Sullivan V, S C Sri Harsha P, Brennan L. Effects of a casein hydrolysate versus intact casein on gastric emptying and amino acid responses. Eur J Nutr. 2019;58(3):955-964. View abstract.
Ibero M, Bone J, Martin B, Martinez J. Evaluation of an extensively hydrolysed casein formula (Damira 2000) in children with allergy to cow's milk proteins. Allergol Immunopathol (Madr) 2010;38(2):60-8. View abstract.
Iskedjian M, Szajewska H, Spieldenner J, et al. Meta-analysis of a partially hydrolysed 100%-whey infant formula vs. extensively hydrolysed infant formulas in the prevention of atopic dermatitis. Curr Med Res Opin 2010;26(11):2599-606. View abstract.
Jakobsson I, Lothe L, Ley D, Borschel MW. Effectiveness of casein hydrolysate feedings in infants with colic. Acta Paediatr 2000;89(1):18-21. View abstract.
Jonker JT, Wijngaarden MA, Kloek J, et al. Effects of low doses of casein hydrolysate on post-challenge glucose and insulin levels. Eur J Intern Med 2011;22(3):245-8. View abstract.
Kim HJ, Kim J, Lee S, et al. A Double-Blind, Randomized, Placebo-Controlled Crossover Clinical Study of the Effects of Alpha-s1 Casein Hydrolysate on Sleep Disturbance. Nutrients. 2019;11(7):1466. View abstract.
Knip M, Virtanen SM, Becker D, et al. Early feeding and risk of type 1 diabetes: Experiences from the Trial to Reduce Insulin-dependent diabetes mellitus in the Genetically at Risk (TRIGR). Am J Clin Nutr 2011;94(6 Suppl):1814S-1820S. View abstract.
Knip M, Virtanen SM, Seppa K, et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med 2010;363(20):1900-8. View abstract.
Koopman R, Crombach N, Gijsen AP, et al. Ingestion of a protein hydrolysate is accompanied by an accelerated in vivo digestion and absorption rate when compared with its intact protein. Am J Clin Nutr 2009;90(1):106-15. View abstract.
Laatikainen R, Salmenkari H, Sibakov T, Vapaatalo H, Turpeinen A. Randomised Controlled Trial: Partial Hydrolysation of Casein Protein in Milk Decreases Gastrointestinal Symptoms in Subjects with Functional Gastrointestinal Disorders. Nutrients. 2020;12(7):2140. View abstract.
Mallet E, Henocq A. Long-term prevention of allergic diseases by using protein hydrolysate formula in at-risk infants. J Pediatr 1992;121(5 Pt 2):S95-100. View abstract.
Manders RJ, Hansen D, Zorenc AH, et al. Protein co-ingestion strongly increases postprandial insulin secretion in type 2 diabetes patients. J Med Food 2014;17(7):758-63. View abstract.
Manders RJ, Koopman R, Sluijsmans WE, et al. Co-ingestion of a protein hydrolysate with or without additional leucine effectively reduces postprandial blood glucose excursions in type 2 diabetic men. J Nutr 2006;136(5):1294-9. View abstract.
Manders RJ, Praet SF, Meex RC, et al. Protein hydrolysate/leucine co-ingestion reduces the prevalence of hyperglycemia in type 2 diabetic patients. Diabetes Care 2006;29(12):2721-2. View abstract.
Manders RJ, Praet SF, Vikstrom MH, et al. Protein hydrolysate co-ingestion does not modulate 24 h glycemic control in long-standing type 2 diabetes patients. Eur J Clin Nutr 2009;63(1):121-6. View abstract.
Manders RJ, Wagenmakers AJ, Koopman R, et al. Co-ingestion of a protein hydrolysate and amino acid mixture with carbohydrate improves plasma glucose disposal in patients with type 2 diabetes. Am J Clin Nutr 2005;82(1):76-83. View abstract.
Nishi T, Hara H, Hira T, Tomita F. Dietary protein peptic hydrosylates stimulate cholecystokinin release via direct sensing by rat intestinal mucosal cells. Exp Biol Med (Maywood) 2001;226:1031-6. View abstract.
Oldaeus G, Anjou K, Bjorksten B, et al. Extensively and partially hydrolysed infant formulas for allergy prophylaxis. Arch Dis Child 1997;77(1):4-10. View abstract.
Park O, Swaisgood HE, Allen JC. Calcium binding of phosphopeptides derived from hydrolysis of alpha s-casein or beta-casein using immobilized trypsin. J Dairy Sci 1998;81:2850-7. View abstract.
Pedrosa M, Pascual CY, Larco JI, Esteban MM. Palatability and hydrolysates and other substitution formulas for cow's milk-allergic children: a comparative study of taste, smell, and texture evaluated by healthy volunteers. J Investig Allergol Clin Immunol 2006;16(6):351-6. View abstract.
Qin LQ, Xu JY, Dong JY, Zhao Y, van Bladeren P, Zhang W. Lactotripeptides intake and blood pressure management: a meta-analysis of randomised controlled clinical trials. Nutr Metab Cardiovasc Dis. 2013;23(5):395-402. View abstract.
Roy CC, Darling P. Pitfalls in the design and manufacture of infant formulas. J Pediatr Gastroenterol Nutr 1983;2 Suppl 1:S282-92. View abstract.
Rzehak P, Sausenthaler S, Koletzko S, et al. Short- and long-term effects of feeding hydrolyzed protein infant formulas on growth at = 6 y of age: Results from the German Infant Nutritional Intervention Study. Am J Clin Nutr 2009;89(6):1846-56. View abstract.
Sakata Y, Yoshida C, Fujiki Y, et al. Effects of Casein Hydrolysate Ingestion on Thermoregulatory Responses in Healthy Adults during Exercise in Heated Conditions: A Randomized Crossover Trial. Nutrients. 2020;12(3):867. View abstract.
Sampson HA, Bernhisel-Broadbent J, Yang E, Scanlon SM. Safety of casein hydrolysate formula in children with cow milk allergy. J Pediatr 1991;118(4 Pt 1):520-5. View abstract.
Saunders MJ, Moore RW, Kies AK, et al. Carbohydrate and protein hydrolysate coingestions improvement of late-exercise time-trial performance. Int J Sport Nutr Exerc Metab 2009;19(2):136-49. View abstract.
Tauzin J, Miclo L, Gaillard JL. Angiotensin-I-converting enzyme inhibitory peptides from tryptic hydrolysate of bovine alphaS2-casein. FEBS Lett 2002;531:369-74. View abstract.
Terheggen-Lagro SW, Khouw IM, Schaafsma A, Wauters EA. Safety of a new extensively hydrolysed formula in children with cow's milk protein allergy: a double blind crossover study. BMC Pediatr 2002;2:10. View abstract.
Townsend RR, McFadden CB, Ford V, Cadee JA. A randomized, double-blind, placebo-controlled trial of casein protein hydrolysate (C12 peptide) in human essential hypertension. Am J Hypertens 2004;17(11 Pt 1):1056-8. View abstract.
Turpeinen AM, Järvenpää S, Kautiainen H, Korpela R, Vapaatalo H. Antihypertensive effects of bioactive tripeptides-a random effects meta-analysis. Ann Med. 2013;45(1):51-6. View abstract.
Verdijk LB, Jonkers RA, Gleeson BG, et al. Protein supplementation before and after exercise does not further augment skeletal muscle hypertrophy after resistance training in elderly men. Am J Clin Nutr 2009;89(2):608-16. View abstract.
von Berg A, Filipiak-Pittroff B, Kramer U, et al. Preventive effect of hydrolyzed infant formulas persists until age 6 years: long-term results from the German Infant Nutritional Intervention Study (GINI). J Allergy Clin Immunol 2008;121(6):1442-7. View abstract.
von Berg A, Koletzko S, Filipiak-Pittroff B, et al. Certain hydrolyzed formulas reduce the incidence of atopic dermatitis but not that of asthma: three-year results of the German Infant Nutritional Intervention Study. J Allergy Clin Immunol 2007;119(3):718-25. View abstract.
von Berg A, Koletzko S, Grubl A, et al. The effect of hydrolyzed cow's milk formula for allergy prevention in the first year of life: the German Infant Nutritional Intervention Study, a randomized double-blind trial. J Allergy Clin Immunol 2003;111(3):533-40. View abstract.
Wal JM. Cow's milk proteins/allergens. Ann Allergy Asthma Immunol 2002;89:3-10. View abstract.
Wal JM. Structure and function of milk allergens. Allergy 2001;56:35-8. View abstract.
Yamamoto N. Antihypertensive peptides derived from foods. Biopoly 1997;43:129-34.
You Might Also Like
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2020.